ISR Holding AB: The Host in the Centre of Attention - Redeye

Redeye initiates coverage of ISR Immune System Regulation Holding AB, a Swedish biotech company developing an HIV treatment and a nasally inhaled COVID-19 vaccine, both of which we believe can prompt a paradigm shift in the current standard of care. ISR awaits clinical phase IIa trial data for its HIV study and approval to initiate a clinical phase I/II trial for its COVID-19 vaccine. We view the current share price as an attractive entry opportunity for long-term-oriented investors.

Länk till analysen i sin helhet: https://www.redeye.se/research/839737/isr-holding-ab-the-host-in-the-centre-of-attention?utm_source=finwire&utm_medium=RSS